REFERENCES
- Barthel W., Hüller G, Haustein K. O., et al. Bioequivalence of Allopurinol-containing tablet preparations. Int. J. Clin. Pharmacol. Ther. 1999; 37(3)148–152
- Chen M. L., André J. J. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res. 1991; 8(1)25–32
- Chen C. M., Lee D. Y., Xie J. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ [P]. US Patent: 5736159, 1998-04-07, 1998
- FDA. 1995. Guidance for Industry: SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (I).
- Goldenberg M. M. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999; 21(4)634–642
- Gupta S. K., Shah J. C., Guinta D., et al. Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrocholoride formulations. J. Clin. Pharmacol. 1998; 38(1)60–67
- Hou H. M., Zhu J. P. The preparation and in vitro release of OROS(indometacin). Chin. J. Hospital Pharm. 1982; 2(5)265–266
- Keith S. Advances in psychotropic formulations. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2006; 30(6)996–1008
- Kuczynski A. L., Ayer A. D., Wong P. S. L., et al. Oral hypoglycemic glipizide granulation [P]. US:5024843, 1991-06-18, 1991
- Liu L., Ku J., Khang G., et al. Nifedipine controlled delivery by sandwished osmotic tablet system. J. Control. Release. 2000; 68(2)145–156
- Modi N. B., Lindemulder B., Gupta S. K. Single- and multi-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J. Clin. Pharmacol. 2000; 40(4)379–388
- Okimoto K., Miyake M., Ohnishi N. Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug using (SBE)7m-β-CD. Pharm. Res. 1998; 15(10)1562–1568
- Okimoto K., Rajewski R. A., Stella V. J. Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)7m-β-CD as both a solubilizing and osmotic agent. J. Control. Release. 1999; 60(2–3)311–319
- Okimoto K., Rajewski R. A., Stella V. J. Release of testosterone from an osmotic pump tablets (OPT) utilizing (SBE)7m-β-cyclodextrin as both a solubilizing and osmotic pump agent. J. Control. Release. 1999; 58(1)29–38
- Okimoto K., Rajewski R. A., Stella V. J. Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-β-CD. Pharm. Res. 1999; 16(4)549–554
- Swanson D. R., Barclay B. L., Wong P. S. L., et al. Nifedipine gastrointestinal therapeutic system. Am. J. Med. 1987; 83: 3
- Thombre A. G., Appel L. E., Chidlaw M. B., et al. Osmotic drug delivery using swellable- core technology. J. Control. Release. 2004; 75: 75–89
- Verma R. K., Krishna D. M., Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Release 2000b; 79: 7–27
- Verma R. K., Mishra B., Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 2000a; 26(7)695–708
- Walter-Sack I., de Vries J. X., Ernst B., et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients. Therapeutic equivalence to allopurinol. J. Rheumatol. 1996; 23: 498–501
- Walter-Sack I., de Vries J. X., Kreiner C., et al. Disposition and uric acid lowering effect of oxipurinol: Comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur. J. Clin. Pharmacol. 1995; 49: 215–220